Stromal cell-derived factor 1 (SDF-1)

Modality

Stromal cell-derived factor 1 (SDF-1)

Stromal cell-derived factor 1 (SDF-1), also known as C-X-C motif chemokine 12 (CXCL12), is a chemokine protein that can activate STAT3 and Akt signaling ways and protect the heart from ischemia-reperfusion injury. As a secreted 89-amino acid protein, SDF-1/CXCL12 binds to chemokine receptor type 4 (CXCR4), a seven-pass G-protein-coupled membrane receptor.

SDF-1 is generated in two forms: SDF-1α/CXCL12a and SDF-1β/CXCL12b. Chemokines are labelled by the presence of four conserved cysteines forming two disulfide bonds. The former one, SDF-1/CXCL12 protein, belong to the CXC class of chemokines, whose original pair of cysteines are separated by one intervening amino acid. Furthermore, the first eight residues at the N-terminal end of SDF-1/CXCL12 provide receptor binding sites, but only Lys-1 and Pro-2 are directly involved in receptor activation.

Potential Applications of SDF-1

SDF-1/CXCL12 recruits cardiac and bone marrow-derived stem cells and appears to stimulate cardiac angiogenesis and vasculogenesis in a paracrine way. Recombinant SDF-1/CXCL12 or recombinant vectors (e.g. plasmids) encoding SDF-1/CXCL12 have been developed for the treatment of peripheral arterial disease (PAD) in preclinical and clinical trials.

A phase I clinical trial (NCT01082094) showed no significant safety concerns related to gene transfer of a DNA plasmid encoding human SDF-1.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for SDF-1

SDF-1 Pipelines

Generic Name	Brand Name/ Alternative Name	Indications	Manufacturer	Latest Stage
JVS-100	GP51801	Peripheral arterial disease, Heart failure, Peripheral ischemia, Perioperative ischemia, Surgical wounds, Fecal incontinence	Nanjing Jiqun Biotechnology, Juventas Therapeutics.	Phase II
4P-021	Pending update	novel coronavirus infection	4P-Pharma	Phase II
AD-214	Pending update	Gastroesophageal Reflux, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease	AdAlta Ltd., Addpharma.	Phase I
CK-0804	Pending update	primary myelofibrosis	Cellenkos.	Phase I
MB-1707	Pending update	Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumors	Mainline Biosciences.	Phase I
Auto immune disease therapy	Pending update	autoimmune disease	Ermium Therapeutics SAS	Pre-clinical
GP 01CR11	Pending update	tumor	GPCR Co., Ltd.	Pre-clinical
GP-01CR21	Pending update	tumor	GPCR Co., Ltd.	Pre-clinical

All Categories

Stromal cell-derived factor 1 (SDF-1)

Modality